Get the Stockscreener App
416.04
1.86%
-7.89
After Hours:
416.05
0.010
+0.00%
Medpace Holdings Inc stock is traded at $416.04, with a volume of 655.79K.
It is down -1.86% in the last 24 hours and down -30.57% over the past month.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
See More
Previous Close:
$423.93
Open:
$397
24h Volume:
655.79K
Relative Volume:
2.34
Market Cap:
$11.81B
Revenue:
$2.36B
Net Income/Loss:
$433.01M
P/E Ratio:
29.10
EPS:
14.2984
Net Cash Flow:
$676.77M
1W Performance:
-23.14%
1M Performance:
-30.57%
6M Performance:
-9.42%
1Y Performance:
+23.65%
1-Day Range:
$392.35
$420.42
1-Week Range:
$392.35
$550.62
52-Week Range:
$250.05
$628.92
Medpace Holdings Inc Stock (MEDP) Company Profile
Name
Medpace Holdings Inc
Sector
Industry
Phone
(513) 579-9911
Address
5375 MEDPACE WAY, CINCINNATI, OH
Compare MEDP vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MEDP
Medpace Holdings Inc
|
416.04 | 12.03B | 2.36B | 433.01M | 676.77M | 14.30 |
|
TMO
Thermo Fisher Scientific Inc
|
509.82 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
214.94 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
617.20 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.88 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.83 | 32.29B | 3.17B | 642.63M | 539.81M | 10.77 |
Medpace Holdings Inc Stock (MEDP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Oct-02-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Sep-03-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-29-25 | Downgrade | UBS | Neutral → Sell |
| Jul-23-25 | Downgrade | TD Cowen | Hold → Sell |
| Jun-24-25 | Initiated | Barclays | Equal Weight |
| Apr-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-24-25 | Initiated | Leerink Partners | Market Perform |
| Oct-23-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-27-24 | Downgrade | UBS | Buy → Neutral |
| Sep-25-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-24 | Initiated | Truist | Hold |
| May-29-24 | Initiated | TD Cowen | Buy |
| May-28-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-24 | Initiated | Deutsche Bank | Hold |
| Feb-15-24 | Upgrade | UBS | Neutral → Buy |
| Oct-24-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-08-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-27-22 | Upgrade | UBS | Sell → Neutral |
| Sep-07-22 | Initiated | UBS | Sell |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Oct-02-20 | Upgrade | Truist | Hold → Buy |
| Jun-08-20 | Upgrade | Robert W. Baird | Underperform → Neutral |
| May-13-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Apr-30-20 | Upgrade | SunTrust | Sell → Hold |
| Apr-20-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Mar-17-20 | Downgrade | SunTrust | Hold → Sell |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Oct-31-18 | Upgrade | SunTrust | Hold → Buy |
| Sep-17-18 | Initiated | SunTrust | Hold |
| Jul-31-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-01-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-29-17 | Initiated | Raymond James | Mkt Perform |
| Jul-10-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
View All
Medpace Holdings Inc Stock (MEDP) Latest News
Medpace outlines 2026 revenue growth of up to 12.8% amid backlog normalization and metabolic trial shifts - MSN
Medpace Holdings, Inc. (NASDAQ:MEDP) Q4 2025 Earnings Call Transcript - Insider Monkey
Baird upgrades Medpace stock rating to Outperform on AI potential By Investing.com - Investing.com Australia
4 Analysts Have This To Say About Medpace Hldgs - Benzinga
Baird upgrades Medpace stock rating to Outperform on AI potential - Investing.com
Deutsche Bank Adjusts Medpace Price Target to $480 From $600, Maintains Hold Rating - marketscreener.com
Truist Securities Adjusts Price Target on Medpace to $539 From $555, Maintains Hold Rating - marketscreener.com
Medpace stock price target lowered to $460 by BMO Capital - Investing.com South Africa
Medpace (NASDAQ:MEDP) Given New $500.00 Price Target at Barclays - MarketBeat
Medpace stock price target lowered to $460 by BMO Capital By Investing.com - Investing.com India
Leerink Partners Issues Pessimistic Forecast for Medpace (NASDAQ:MEDP) Stock Price - MarketBeat
Medpace (NASDAQ:MEDP) Price Target Lowered to $539.00 at Truist Financial - MarketBeat
Madison Asset Management LLC Sells 4,419 Shares of Medpace Holdings, Inc. $MEDP - MarketBeat
Candriam S.C.A. Decreases Stake in Medpace Holdings, Inc. $MEDP - MarketBeat
Medpace Q4 2025 slides: Revenue up 32%, stock tumbles on guidance By Investing.com - Investing.com South Africa
Medpace Q4 Earnings Beat Overshadowed by Cancellation Spike - AlphaStreet News
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial - Yahoo Finance
Decoding Medpace Holdings Inc (MEDP): A Strategic SWOT Insight - GuruFocus
Medpace (MEDP) Stock Declines Significantly - GuruFocus
Medpace Q4 2025 slides: Revenue up 32%, stock tumbles on guidance - Investing.com Nigeria
Medpace Holdings’ Earnings Call Signals Growth Amid Volatility - TipRanks
Medpace (MEDP) Sees Upgrade Despite Stock Decline - GuruFocus
Leerink Partners lowers Medpace stock price target on elevated cancellations By Investing.com - Investing.com India
Leerink Partners lowers Medpace stock price target on elevated cancellations - Investing.com
Medpace Holdings Inc (MEDP) Q4 2025 Earnings Call Highlights: St - GuruFocus
U.S. Markets Ended Tuesday Mixed As Spotify Technology Led, Medpace Holdings Lagged - Barron's
Medpace Q4 Earnings Call Highlights - MarketBeat
Medpace (NASDAQ:MEDP) Raised to "Outperform" at Robert W. Baird - MarketBeat
Medpace (MEDP) Q4 2025 Earnings Call Transcript - AOL.com
Medpace Holdings Inc (NASDAQ:MEDP) Issues Inline Guidance - FXDailyReport.Com
Medpace (NASDAQ:MEDP) Shares Gap DownTime to Sell? - MarketBeat
Medpace Holdings Inc (MEDP) Shares Down 16.15% on Feb 10 - GuruFocus
Medpace (MEDP) Shares Drop Despite Beating Q4 Expectations - GuruFocus
Medpace slumps after Q4 earnings on book-to-bill ratio (MEDP:NASDAQ) - Seeking Alpha
Earnings call transcript: Medpace Q4 2025 beats expectations, stock drops By Investing.com - Investing.com South Africa
Earnings call transcript: Medpace Q4 2025 beats expectations, stock drops - Investing.com
Envestnet Asset Management Inc. Grows Stock Holdings in Medpace Holdings, Inc. $MEDP - MarketBeat
Medpace Holdings revenue up 32.0% to USD 708.5M in Q4 2025 - Medical Buyer
Medpace Holdings: Great Quarter, Stale Backlog, Full Valuation (NASDAQ:MEDP) - Seeking Alpha
Medpace Holdings, Inc. Q4 Income Advances, Beats Estimates - Nasdaq
Medpace (NASDAQ:MEDP) Releases FY 2026 Earnings Guidance - MarketBeat
Medpace (MEDP) Surpasses Q4 Earnings and Revenue Expectations - GuruFocus
Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results - Investing News Network
Medpace shares tumble 5% despite Q4 earnings beat, in-line guidance By Investing.com - Investing.com South Africa
Medpace shares tumble 5% despite Q4 earnings beat, in-line guidance - Investing.com UK
Medpace: Fourth Quarter Financial Overview - Bitget
Medpace Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Medpace (NASDAQ:MEDP) Reports Bullish Q4 CY2025 - Yahoo Finance
Medpace (NASDAQ:MEDP) Releases Quarterly Earnings Results, Beats Estimates By $0.49 EPS - MarketBeat
Medpace: Q4 Earnings Snapshot - KVUE
Medpace Holdings Inc Stock (MEDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):